{"id":12992,"date":"2024-02-06T09:56:15","date_gmt":"2024-02-06T08:56:15","guid":{"rendered":"https:\/\/www.tauli.cat\/institut\/?page_id=12992"},"modified":"2025-01-27T12:53:05","modified_gmt":"2025-01-27T11:53:05","slug":"plataforma-de-terapies-avancades","status":"publish","type":"page","link":"https:\/\/www.tauli.cat\/institut\/plataformes-i-serveis\/plataforma-de-terapies-avancades\/","title":{"rendered":"Plataforma de Ter\u00e0pies Avan\u00e7ades"},"content":{"rendered":"<div class=\"wpb-content-wrapper\">[vc_row section_id=&#8221;custom-top-tabs&#8221;][vc_column][vc_column_text el_class=&#8221;top-tabs&#8221;]\n<ul>\n<li data-hash=\"presentacio\">Presentaci\u00f3<\/li>\n<li data-hash=\"serveis\">Projectes<\/li>\n<li data-hash=\"contacte\">Contacte<\/li>\n<\/ul>\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=&#8221;custom-top-tabs-content&#8221;][vc_column width=&#8221;2\/3&#8243;][vc_column_text]La <strong>Plataforma de Ter\u00e0pies Avan\u00e7ades<\/strong> t\u00e9 com a principal objectiu impulsar el <strong>desenvolupament i la implementaci\u00f3 de noves ter\u00e0pies al Parc Taul\u00ed<\/strong>, per accelerar la transfer\u00e8ncia de descobriments cient\u00edfics a la pr\u00e0ctica cl\u00ednica, impulsant ter\u00e0pies m\u00e9s eficients i personalitzades. Per fer-ho possible, la plataforma promou els assaigs cl\u00ednics, la recerca i la innovaci\u00f3 per validar l&#8217;efic\u00e0cia i seguretat d\u2019aquestes ter\u00e0pies, seguint la l\u00ednia estrat\u00e8gica establerta pel Parc Taul\u00ed.<\/p>\n<p>La Plataforma funciona sota la coordinaci\u00f3 de:<\/p>\n<ul>\n<li><a href=\"https:\/\/www.tauli.cat\/hospital\/centre-de-medicina-genomica\" target=\"_blank\" rel=\"noopener\">Centre de Medicina Gen\u00f2mica<\/a><\/li>\n<li><a href=\"https:\/\/www.tauli.cat\/institut\/plataformes-i-serveis\/unitat-assajos-clinics\/\" target=\"_blank\" rel=\"noopener\">Unitat de Suport als Assaigs Cl\u00ednics<\/a> (USAC)<\/li>\n<li><a href=\"https:\/\/www.tauli.cat\/hospital\/farmacia\" target=\"_blank\" rel=\"noopener\">Servei de Farm\u00e0cia<\/a><\/li>\n<\/ul>\n<p>La Unitat de Farmacogen\u00f2mica i Ter\u00e0pies avan\u00e7ades, dins el Centre de Medicina Gen\u00f2mica, ser\u00e0 la unitat responsable de supervisar l\u2019activitat d\u2019assaigs cl\u00ednics en ter\u00e0pies avan\u00e7ades.<\/p>\n<p>Aix\u00ed mateix, el grup de treball de Ter\u00e0pies Avan\u00e7ades dona suport a la Plataforma de Ter\u00e0pies Avan\u00e7ades, en col\u00b7laboraci\u00f3 entre l\u2019Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT) i el Centre de Medicina Gen\u00f2mica. Conjuntament han elaborat el <strong>Pla Funcional per impulsar els assaigs cl\u00ednics de Fase I i de Ter\u00e0pies Avan\u00e7ades i Personalitzades<\/strong>.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/3&#8243;]\r\n\t\t<div class=\"eut-team eut-element team\" style=\"\">\r\n\t\t\t<figure>\r\n\t\t\t\t\t\t\t\t<div class=\"eut-team-person eut-media eut-align-center\">\r\n\t\t\t\t\t<img width=\"362\" height=\"383\" src=\"https:\/\/www.tauli.cat\/institut\/wp-content\/uploads\/2023\/04\/Victor-MG.jpg\" class=\"attachment-large size-large\" alt=\"\" decoding=\"async\" loading=\"lazy\" srcset=\"https:\/\/www.tauli.cat\/institut\/wp-content\/uploads\/2023\/04\/Victor-MG.jpg 362w, https:\/\/www.tauli.cat\/institut\/wp-content\/uploads\/2023\/04\/Victor-MG-284x300.jpg 284w\" sizes=\"(max-width: 362px) 100vw, 362px\" \/>\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<figcaption>\r\n\t\t\t\t\t<div class=\"eut-team-description eut-align-center\">\r\n\t\t\t\t\t\t<div class=\"eut-team-identity eut-subtitle\">Responsable<\/div>\r\n\t\t\t\t\t\t\t\t\t\t\t\t<h5 class=\"eut-team-name\">V\u00edctor M Mart\u00ednez-Gonz\u00e1lez<\/h5>\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"eut-team-content\"><a href=\"mailto:vmmartinez@tauli.cat\">vmmartinez@tauli.cat<\/a><\/p>\r\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t<\/figcaption>\r\n\t\t\t<\/figure>\r\n\t\t<\/div>\r\n\r\n\t\t[\/vc_column][\/vc_row][vc_row el_class=&#8221;custom-top-tabs-content&#8221;][vc_column][vc_column_text]Actualment, el Parc Taul\u00ed participa en <strong>quatre assaigs cl\u00ednics<\/strong> i du a terme <strong>estudis d&#8217;investigaci\u00f3 en ter\u00e0pies avan\u00e7ades<\/strong>, presentats en la taula seg\u00fcent:[\/vc_column_text][vc_column_text]\n<table style=\"width: 56.4806%;\" width=\"1376\">\n<tbody>\n<tr>\n<td style=\"width: 98.606%;\" colspan=\"10\" width=\"1376\">\n<h5><strong>Ter\u00e0pies Avan\u00e7ades al Parc Taul\u00ed<\/strong><\/h5>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 13.3529%;\" width=\"56\"><\/td>\n<td style=\"width: 16.5077%;\" width=\"298\"><strong>Estudi<\/strong><\/td>\n<td style=\"width: 13.9398%;\" width=\"298\"><\/td>\n<td style=\"width: 6.38298%;\" width=\"96\"><strong>EudraCT Number<\/strong><\/td>\n<td style=\"width: 8.65737%;\" width=\"87\"><strong>Promotor<\/strong><\/td>\n<td style=\"width: 7.77696%;\" width=\"77\"><strong>IP<\/strong><\/td>\n<td style=\"width: 8.65737%;\" width=\"116\"><strong>G\u00e8nica<\/strong><\/td>\n<td style=\"width: 8.1438%;\" width=\"116\"><strong>Cel\u00b7lular<\/strong><\/td>\n<td style=\"width: 6.82318%;\" width=\"116\"><strong>Tissular<\/strong><\/td>\n<td style=\"width: 8.3639%;\" width=\"116\"><strong>Combinat<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 13.3529%;\" width=\"56\"><strong>DHELIVER<\/strong><\/td>\n<td style=\"width: 16.5077%;\" width=\"298\">Estudi aleatoritzat, controlat amb placebo, doble cec, multic\u00e8ntric de fase IIb per avaluar l&#8217;efic\u00e0cia i la seguretat de HepaStem en pacients amb insufici\u00e8ncia hep\u00e0tica aguda i cr\u00f2nica (ACLF) \u2013 DHELIVER.<\/td>\n<td style=\"width: 13.9398%;\" width=\"298\">Fase IIb<\/td>\n<td style=\"width: 6.38298%;\" width=\"96\">2019-003051-11<\/td>\n<td style=\"width: 8.65737%;\" width=\"87\">Promethera Therapeutics<\/td>\n<td style=\"width: 7.77696%;\" width=\"77\">Jordi S\u00e1nchez Delgado<\/td>\n<td style=\"width: 8.65737%;\" width=\"116\"><\/td>\n<td style=\"width: 8.1438%;\" width=\"116\">Allogeneic off-the-shelf, liver-derived stem cell therapy<\/td>\n<td style=\"width: 6.82318%;\" width=\"116\"><\/td>\n<td style=\"width: 8.3639%;\" width=\"116\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 13.3529%;\" width=\"56\"><strong>TANGELO (BP41674)<\/strong><\/td>\n<td style=\"width: 16.5077%;\" width=\"298\">Estudi obert, multic\u00e8ntric per avaluar la seguretat, torelabilitat, farmacocin\u00e8tica i farmacodin\u00e0mia de RO7248824 en participants amb S\u00edndrome d&#8217;Angelman.<\/td>\n<td style=\"width: 13.9398%;\" width=\"298\">Fase I<\/td>\n<td style=\"width: 6.38298%;\" width=\"96\">2019-003787-48<\/td>\n<td style=\"width: 8.65737%;\" width=\"87\">Roche Farma<\/td>\n<td style=\"width: 7.77696%;\" width=\"77\">Ana Roche Mart\u00ednez<\/td>\n<td style=\"width: 8.65737%;\" width=\"116\">UBE3A-LNA (Locked nucleic acid)<\/td>\n<td style=\"width: 8.1438%;\" width=\"116\"><\/td>\n<td style=\"width: 6.82318%;\" width=\"116\"><\/td>\n<td style=\"width: 8.3639%;\" width=\"116\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 13.3529%;\" width=\"56\"><strong>GTX-102-001<\/strong><\/td>\n<td style=\"width: 16.5077%;\" width=\"298\">Assaig cl\u00ednic de fase 1\/2, obert, de dosis m\u00faltiples i d&#8217;augment gradual de la dosi per avaluar la seguretat i la tolerabilitat de GTX-102 en pacients pedi\u00e0trics amb s\u00edndrome d&#8217;Angelman (SA).<\/td>\n<td style=\"width: 13.9398%;\" width=\"298\">Fase I\/II<\/td>\n<td style=\"width: 6.38298%;\" width=\"96\">2021-001793-36<\/td>\n<td style=\"width: 8.65737%;\" width=\"87\">Ultragenyx Pharmaceutical Inc.<\/td>\n<td style=\"width: 7.77696%;\" width=\"77\">Ana Roche Mart\u00ednez<\/td>\n<td style=\"width: 8.65737%;\" width=\"116\">Antisense oligonucleotide (ASO)<\/td>\n<td style=\"width: 8.1438%;\" width=\"116\"><\/td>\n<td style=\"width: 6.82318%;\" width=\"116\"><\/td>\n<td style=\"width: 8.3639%;\" width=\"116\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 13.3529%;\" width=\"56\"><strong>FIDELIA (ZYA38771 )<\/strong><\/td>\n<td style=\"width: 16.5077%;\" width=\"298\">Implantaci\u00f3 de c\u00e8l\u00b7lules derivades del m\u00fascul esquel\u00e8tic per al tractament de la incontin\u00e8ncia fecal: un estudi cl\u00ednic de fase III, aleatoritzat, controlat, doble cec i dos bra\u00e7os de tractament.<\/td>\n<td style=\"width: 13.9398%;\" width=\"298\">Fase III<\/td>\n<td style=\"width: 6.38298%;\" width=\"96\">2021-001376-42<\/td>\n<td style=\"width: 8.65737%;\" width=\"87\">Innovacell AG<\/td>\n<td style=\"width: 7.77696%;\" width=\"77\">Laura Mora L\u00f3pez<\/td>\n<td style=\"width: 8.65737%;\" width=\"116\"><\/td>\n<td style=\"width: 8.1438%;\" width=\"116\">Skeletal Muscle-Derived Cell Implantation<\/td>\n<td style=\"width: 6.82318%;\" width=\"116\"><\/td>\n<td style=\"width: 8.3639%;\" width=\"116\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 13.3529%;\" width=\"56\"><strong>Nano4Sepsis\/NanoCares<\/strong><\/td>\n<td style=\"width: 16.5077%;\" width=\"298\"><\/td>\n<td style=\"width: 13.9398%;\" width=\"298\"><\/td>\n<td style=\"width: 6.38298%;\" width=\"96\"><\/td>\n<td style=\"width: 8.65737%;\" width=\"87\">Fundaci\u00f3n Ram\u00f3n Areces, I3PT, ESICM. Actualment sol\u00b7licitat a La Caixa Health Research 2023 i preparant el projecte per a les AES 2024<\/td>\n<td style=\"width: 7.77696%;\" width=\"77\">Antonio Artigas\/Marta Camprub\u00ed-Rimblas<\/td>\n<td style=\"width: 8.65737%;\" width=\"116\"><\/td>\n<td style=\"width: 8.1438%;\" width=\"116\"><\/td>\n<td style=\"width: 6.82318%;\" width=\"116\"><\/td>\n<td style=\"width: 8.3639%;\" width=\"116\">Nanoc\u00e0psules<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=&#8221;custom-top-tabs-content&#8221;][vc_column width=&#8221;2\/5&#8243;][vc_column_text css=&#8221;&#8221;]\n<h4>Plataforma de Ter\u00e0pies Avan\u00e7ades<strong><br \/>\n<\/strong><\/h4>\n<p><strong>Institut d&#8217;Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed<\/strong><br \/>\nPla\u00e7a Torre de l&#8217;Aigua, s\/n,<br \/>\n08202 Sabadell<\/p>\n<ul>\n<li class=\"icon-list phone\">93 723 10 10<\/li>\n<li class=\"icon-list fax\"><a href=\"mailto:nalbinana@tauli.cat\">vmmartinez@tauli.cat<\/a><\/li>\n<\/ul>\n[\/vc_column_text][\/vc_column][vc_column width=&#8221;3\/5&#8243; tablet_width=&#8221;7-12&#8243; tablet_sm_width=&#8221;7-12&#8243;][vc_raw_html]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[\/vc_raw_html][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row section_id=&#8221;custom-top-tabs&#8221;][vc_column][vc_column_text el_class=&#8221;top-tabs&#8221;] Presentaci\u00f3 Projectes Contacte [\/vc_column_text][\/vc_column][\/vc_row][vc_row el_class=&#8221;custom-top-tabs-content&#8221;][vc_column width=&#8221;2\/3&#8243;][vc_column_text]La Plataforma de Ter\u00e0pies Avan\u00e7ades t\u00e9 com a principal objectiu impulsar el desenvolupament i la implementaci\u00f3 de noves ter\u00e0pies al Parc Taul\u00ed, per accelerar la transfer\u00e8ncia de descobriments cient\u00edfics a la pr\u00e0ctica cl\u00ednica, impulsant ter\u00e0pies m\u00e9s eficients i personalitzades. Per fer-ho possible, la plataforma promou els assaigs [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":0,"parent":2289,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/pages\/12992"}],"collection":[{"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/comments?post=12992"}],"version-history":[{"count":7,"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/pages\/12992\/revisions"}],"predecessor-version":[{"id":13005,"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/pages\/12992\/revisions\/13005"}],"up":[{"embeddable":true,"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/pages\/2289"}],"wp:attachment":[{"href":"https:\/\/www.tauli.cat\/institut\/wp-json\/wp\/v2\/media?parent=12992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}